Track topics on Twitter Track topics that are important to you
RET mutations and rearrangements have been identified across several solid tumors, including non-small cell lung cancer (NSCLC), and for the first time, a new potent inhibitor shows activity in humans.
Medscape Medical News
Original Article: BLU-667: New Hope for NSCLC and Medullary Thyroid CancerNEXT ARTICLE
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...